We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$871M
AUM Growth
+$146M
Cap. Flow
+$118M
Cap. Flow %
13.5%
Top 10 Hldgs %
47.29%
Holding
141
New
32
Increased
44
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$43.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$32M
3
VTRS icon
Viatris
VTRS
+$17.7M
4
ARGX icon
argenx
ARGX
+$12.1M
5
IMMU
Immunomedics Inc
IMMU
+$9.29M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.4M
2
AMGN icon
Amgen
AMGN
+$18.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.6M
4
BIIB icon
Biogen
BIIB
+$14.5M
5
PFE icon
Pfizer
PFE
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.17%
2 Technology 4.8%
3 Industrials 2.36%
4 Financials 1.58%
5 Materials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
51
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.75M 0.55%
+120,000
New +$4.47M
FSCT
52
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$4.7M 0.54%
124,463
+48,063
+63% +$1.74M
KZR
53
DELISTED
Kezar Life Sciences
KZR
$4.54M 0.52%
21,200
-1,590
-7% -$278K
OBSV
54
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.39M 0.5%
243,669
– –
ABEO icon
55
Abeona Therapeutics
ABEO
$366M
$4.31M 0.5%
13,478
+4,551
+51% +$1.61M
CTMX icon
56
CytomX Therapeutics
CTMX
$675M
$4.31M 0.5%
233,151
+150,009
+180% +$3.42M
TEVA icon
57
Teva Pharmaceuticals
TEVA
$40.8B
$4.31M 0.49%
+200,000
New +$4.64M
DCPH
58
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.26M 0.49%
110,033
+17,002
+18% +$628K
EPZM
59
DELISTED
Epizyme, Inc
EPZM
$4.24M 0.49%
399,502
+92,348
+30% +$1.05M
EVOK
60
DELISTED
Evoke Pharma
EVOK
$4.21M 0.48%
9,798
– –
STRO icon
61
Sutro Biopharma
STRO
$401M
$4.13M 0.47%
+27,500
New +$4.15M
ARVN icon
62
Arvinas
ARVN
$518M
$4.05M 0.46%
+240,000
New +$3.95M
NEOS
63
DELISTED
Neos Therapeutics, Inc
NEOS
$4.03M 0.46%
831,697
+479,555
+136% +$2.72M
ACIU icon
64
AC Immune
ACIU
$223M
$4.03M 0.46%
+503,563
New +$5.06M
SNA icon
65
Snap-on
SNA
$21.2B
$3.98M 0.46%
21,666
+20,300
+1,486% +$3.54M
ACGN
66
DELISTED
Aceragen Inc
ACGN
$3.97M 0.46%
+26,236
New +$3.75M
GOOGL icon
67
Alphabet (Google) Class A
GOOGL
$4.36T
$3.95M 0.45%
65,380
– –
PTLA
68
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.92M 0.45%
147,000
+27,000
+23% +$882K
APLS
69
DELISTED
Apellis Pharmaceuticals
APLS
$3.78M 0.43%
212,470
+101,667
+92% +$1.88M
ORLY icon
70
O'Reilly Automotive
ORLY
$72.9B
$3.77M 0.43%
162,660
– –
ASMB icon
71
Assembly Biosciences
ASMB
$498M
$3.73M 0.43%
+8,369
New +$3.92M
MLNX
72
DELISTED
Mellanox Technologies, Ltd.
MLNX
$3.68M 0.42%
50,093
-35,861
-42% -$2.88M
CBIO
73
Crescent Biopharma
CBIO
$537M
$3.62M 0.42%
2,510
+111
+5% +$168K
ALNY icon
74
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.5M 0.4%
40,000
-155,232
-80% -$15.6M
WHWK
75
Whitehawk Therapeutics
WHWK
$190M
$3.5M 0.4%
75,455
+1,885
+3% +$106K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sphera Funds Management held 141 positions worth $871M, up 20% from $725M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $118M of net new capital in Q3 2018, opening 32 new positions and adding to 44 existing holdings. Its largest new stake was Johnson & Johnson: 325,000 shares worth $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 72% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.6M trimmed.

  • Sphera Funds Management's largest Q3 2018 buy was Johnson & Johnson: 325,000 shares worth $44.9M.
  • Sphera Funds Management added most to Viatris in Q3 2018, an estimated $17.7M increase.
  • Sphera Funds Management's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.6M.
  • Sphera Funds Management fully exited Shire pic in Q3 2018, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $871M portfolio in Q3 2018.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2018.
  • Sphera Funds Management's portfolio value rose 20% quarter-over-quarter to $871M.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.